Canopy Growth Corp
TSX:WEED

Watchlist Manager
Canopy Growth Corp Logo
Canopy Growth Corp
TSX:WEED
Watchlist
Price: 4.1 CAD -0.24%
Market Cap: 539.6m CAD
Have any thoughts about
Canopy Growth Corp?
Write Note

EV/EBIT
Enterprise Value to EBIT

-5.8
Current
-7.8
Median
16.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-5.8
=
Enterprise Value
745.9m CAD
/
EBIT
-127.6m CAD
All Countries
Close
Market Cap EV/EBIT
CA
Canopy Growth Corp
TSX:WEED
543.6m CAD -5.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
749.1B USD 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 23
US
Johnson & Johnson
NYSE:JNJ
348B USD 14.9
US
Merck & Co Inc
NYSE:MRK
251.1B USD 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 13.1
US
Pfizer Inc
NYSE:PFE
150.1B USD 15.9
EBIT Growth EV/EBIT to Growth
CA
Canopy Growth Corp
TSX:WEED
Average EV/EBIT: 2 011.2
Negative Multiple: -5.8
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-6.5
2-Years Forward
EV/EBIT
-9.6
3-Years Forward
EV/EBIT
-13.8

See Also

Discover More